Fischer medical ventures Limited has submitted its quarterly compliance certificate to stock exchanges, fulfilling regulatory requirements under SEBI (Depositories and Participants) Regulations, 2018. The filing demonstrates the company's commitment to maintaining transparency and regulatory compliance in its securities operations.

Regulatory Filing Details

The compliance certificate covers the quarter ended March 31, 2026, and was filed under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. Company Secretary and Compliance Officer Balaji Gandla submitted the documentation to both major stock exchanges on April 9, 2026.

RTA Confirmation Certificate

Adroit Corporate Services Pvt. Ltd., serving as the company's Registrar and Share Transfer Agent, issued the confirmation certificate on April 1, 2026. The RTA certificate validates several critical compliance aspects for the quarter ended March 31, 2026.

The confirmation covers key operational areas including:

• Securities received from depository participants for dematerialization were properly confirmed to depositories
• All securities comprised in certificates have been listed on stock exchanges where previously issued securities are traded
• Security certificates received for dematerialization have been mutilated and cancelled after due verification
• Depository names have been substituted in the register of members as registered owners within the mandated 15-day period

Company Information

Compliance Significance

The quarterly compliance certificate represents a mandatory regulatory requirement ensuring proper handling of dematerialized securities. The filing confirms that Fischer Medical Ventures Limited maintains appropriate systems and processes for securities management through its appointed RTA.

The documentation demonstrates the company's adherence to SEBI regulations governing depositories and participants, providing assurance to investors and regulatory authorities about proper securities handling procedures. This routine compliance filing reflects the company's commitment to maintaining regulatory standards in its operations.

Fischer Medical Ventures Limited has filed regulatory disclosures under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations following the conversion of 60 lakh convertible warrants into equity shares worth Rs. 10.53 crores. The conversion, completed through a Board resolution dated March 31, 2026, resulted in changes to promoter shareholding patterns requiring mandatory SAST disclosures.

Warrant Conversion and Allotment Details

The Board of Directors approved the allotment through a Circular Resolution, converting 60,00,000 convertible warrants into an equal number of equity shares. The conversion was executed at an issue price of Rs. 23.40 per share, representing a premium of Rs. 22.40 over the face value of Re. 1 per share.

SEBI SAST Disclosure Requirements

The warrant conversion triggered mandatory disclosures under Regulation 29(2) of SEBI SAST Regulations as it resulted in substantial changes to promoter shareholding. Mr. Shankar Varadharajan, the sole allottee, filed the required disclosures with BSE Limited and National Stock Exchange of India Limited.

Impact on Share Capital Structure

The conversion increased the company's paid-up equity share capital from Rs. 64.85 crores to Rs. 65.45 crores, divided into equity shares of Re. 1 each. The total diluted share capital, considering outstanding convertible securities, stands at Rs. 69.87 crores.

Regulatory Compliance

Fischer Medical Ventures disclosed this development in compliance with Regulation 30 of SEBI LODR Regulations and filed SAST disclosures as required under Regulation 29(2). The company informed both stock exchanges about this material development, ensuring full regulatory compliance. The conversion represents a preferential allotment mode of acquisition, strengthening the promoter group's stake while providing substantial capital infusion to the company.